Vitamin D analogs down-regulate plasminogen activator inhibitor-1 in human coronary artery smooth muscle cells [9]

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 7, 2005, Pages 1545-1546

  Wu Wong, J Ruth ^a   Nakane, M ^a   Ma, J ^a   Cook, A L ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; PARICALCITOL; PLASMINOGEN ACTIVATOR INHIBITOR 1; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; DRUG DERIVATIVE; ERGOCALCIFEROL; VITAMIN D;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; END STAGE RENAL DISEASE; HUMAN; HUMAN CELL; LETTER; MORTALITY; PREVALENCE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VITAMIN SUPPLEMENTATION; BIOSYNTHESIS; CELL CULTURE; CHRONIC KIDNEY FAILURE; CORONARY BLOOD VESSEL; CYTOLOGY; DOWN REGULATION; METABOLISM; PATHOLOGY; RISK;

CALCITRIOL; CELLS, CULTURED; CORONARY VESSELS; DOWN-REGULATION; ERGOCALCIFEROLS; HUMANS; KIDNEY FAILURE, CHRONIC; MYOCYTES, SMOOTH MUSCLE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CALCITRIOL; RISK; VITAMIN D;

EID: 25144512533     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01459.x     Document Type: Letter

References (12)

1. Zebrack JS, Anderson JL, Beddhu S, Horne BD, Bair TL, Cheung A, Muhlestein JB. Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J Am Coll Cardiol 2003; 42: 57-63.
2. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15: 1307-15.
3. Martin KJ, Gonzalez EA. Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. Semin Nephrol 2004; 24: 456-9.
4. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-56.
5. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 115-25.
6. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y. Lower risk for cardiovascular mortality in oral lalpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-84.
7. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002; 8: 1235-42.
8. Cardus A, Gallego C, Muray S, Marco MP, Parisi E, Aldea M, Fernandez E. Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells. Nefrologia 2003; 23: 117-21.
9. Amann K, Ritz C, Adamczak M, Ritz E. Why is coronary heart disease of uraemic patients so frequent and so devastating? Nephrol Dial Transplant 2003; 18: 631-40.
10. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15: 218-23.
11. Nordt TK, Peter K, Ruef J, Kubler W, Bode C. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost 1999; 82: 14-8.
12. Petrie MS, Harrell TE, Schwartz GG, Sane DC. Production of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells: differential responses to calcitriol and paricalcitol. J Thromb Haemost 2004; 2: 2266-7.